Patient-derived granulocyte/macrophage colony-stimulating factor autoantibodies reproduce pulmonary alveolar proteinosis in nonhuman primates

American Journal of Respiratory and Critical Care Medicine

Volumn 182, Issue 1, 2010, Pages 49-61

  Sakagami, Takuro ^a   Beck, David ^a,b   Uchida, Kanji ^a   Suzuki, Takuji ^a   Carey, Brenna C ^a   Nakata, Koh ^c   Keller, Gary ^a   Wood, Robert E ^a   Wert, Susan E ^a   Ikegami, Machiko ^a   Whitsett, Jeffrey A ^a   Luisetti, Maurizio ^d   Davies, Stella ^a   Krischer, Jeffrey P ^e   Brody, Alan ^a   Ryckman, Fred ^a   Trapnell, Fred Ryckman Bruce C ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^d UNIVERSITY OF PAVIA   (Italy)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Alveolar macrophages; Anti granulocyte macrophage colony stimulating factor therapy; Autoimmunity; Neutrophils; Surfactant homeostasis

Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY; IMMUNOGLOBULIN ANTIBODY; LIPID; LUNG SURFACTANT; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; AUTOANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNITY; CELL FUNCTION; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG HALF LIFE; DRUG PURIFICATION; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; LEUKOCYTOSIS; LUNG ALVEOLUS MACROPHAGE; LUNG ALVEOLUS PROTEINOSIS; LUNG LAVAGE; NEUTROPHIL; NONHUMAN; OPEN LUNG BIOPSY; PRIMATE; PRIORITY JOURNAL; PROTEIN DEPLETION; REPRODUCIBILITY; ANIMAL; DISEASE MODEL; ECHOGRAPHY; IMMUNOLOGY; MACACA; PATHOLOGY;

ANIMALS; AUTOANTIBODIES; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODELS, ANIMAL; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MACACA FASCICULARIS; MACROPHAGES, ALVEOLAR; PULMONARY ALVEOLAR PROTEINOSIS;

EID: 77955546518     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201001-0008OC     Document Type: Article

References (58)

1. Rosen SG, Castleman B, Liebow AA. Pulmonary alveolar proteinosis. N Engl J Med 1958;258:1123-1142.
2. Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med 2002;166:215-235. (Pubitemid 34765459)
3. Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med 2003;349:2527-2539.
4. Milleron BJ, Costabel U, Teschler H, Ziesche R, Cadranel JL, Matthys H, Akoun GM. Bronchoalveolar lavage cell data in alveolar proteinosis. Am Rev Respir Dis 1991;144:1330-1332.
5. Seymour JF, Doyle IR, Nakata K, Presneill JJ, Schoch OD, Hamano E, Uchida K, Fisher R, Dunn AR. Relationship of anti-GM-CSF antibody concentration, surfactant protein A and B levels, and serum LDH to pulmonary parameters and response to GM-CSF therapy in patients with idiopathic alveolar proteinosis. Thorax 2003;58:252-257.
6. Suzuki T, Sakagami T, Rubin BK, Nogee LM, Wood RE, Zimmerman SL, Smolarek T, Dishop MK, Wert SE, Whitsett JA, et al. Familial pulmonary alveolar proteinosis caused by mutations in csf2ra. J Exp Med 2008;205:2703-2710.
7. Inoue Y, Trapnell BC, Tazawa R, Arai T, Takada T, Hizawa N, Kasahara Y, Tatsumi K, Hojo M, Ichiwata T, et al. Characteristics of a large cohort of autoimmune pulmonary alveolar proteinosis patients in Japan. Am J Respir Crit Care Med 2008;177:752-762.
8. Wright JR. Clearance and recycling of pulmonary surfactant. Am J Physiol 1990;259:L1-L12.
9. Dranoff G, Crawford AD, Sadelain M, Ream B, Rashid A, Bronson RT, Dickersin GR, Bachurski CJ, Mark EL, Whitsett JA, et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science 1994;264:713-716.
10. Stanley E, Lieschke GJ, Grail D, Metcalf D, Hodgson G, Gall JA, Maher DW, Cebon J, Sinickas V, Dunn AR. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci USA 1994;91:5592-5596.
11. Robb L, Drinkwater CC, Metcalf D, Li R, Kontgen F, Nicola NA, Begley CG. Hematopoietic and lung abnormalities in mice with a null mutation of the common beta subunit of the receptors for granulocyte-macrophage colony-stimulating factor and interleukins 3 and 5. Proc Natl Acad Sci USA 1995;92:9565-9569.
12. Ikegami M, Ueda T, Hull W, Whitsett JA, Mulligan RC, Dranoff G, Jobe AH. Surfactant metabolism in transgenic mice after granulocyte macrophage-colony stimulating factor ablation. Am J Physiol 1996;270:L650-L658.
13. Yoshida M, Ikegami M, Reed JA, Chroneos ZC, Whitsett JA. GM-CSF regulates surfactant protein-a and lipid catabolism by alveolar macrophages. Am J Physiol 2001;280:L379-L386. (Pubitemid 32473186)
14. Golde DW, Territo M, Finley TN, Cline MJ. Defective lung macrophages in pulmonary alveolar proteinosis. Ann Intern Med 1976;85:304-309.
15. Uchida K, Nakata K, Suzuki T, Luisetti M, Watanabe M, Koch DE, Stevens CA, Beck DC, Denson LA, Carey BC, et al. Granulocyte/macrophage colony-stimulating factor autoantibodies and myeloid cell in healthy individuals. Blood 2009;113:2547-2556.
16. Berclaz PY, Carey B, Fillipi MD, Wernke-Dollries K, Geraci N, Cush S, Richardson T, Kitzmiller J, O'Connor M, Hermoyian C, et al. GM-CSF regulates a PU.1-dependent transcriptional program determining the pulmonary response to LPS. Am J Respir Cell Mol Biol 2007;36:114-121.
17. Bonfield TL, Raychaudhuri B, Malur A, Abraham S, Trapnell BC, Kavuru MS, Thomassen MJ. PU.1 regulation of human alveolar macrophage differentiation requires granulocyte-macrophage colony-stimulating factor. Am J Physiol 2003;285:L1132-L1136.
18. Berclaz PY, Zsengeller Z, Shibata Y, Otake K, Strasbaugh S, Whitsett JA, Trapnell BC. Endocytic internalization of adenovirus, nonspecific phagocytosis, and cytoskeletal organization are coordinately regulated in alveolar macrophages by GM-CSF and PU.1. J Immunol 2002;169:6332-6342.
19. Berclaz PY, Shibata Y, Whitsett JA, Trapnell BC. GM-CSF. via PU.1, regulates alveolar macrophage fcgamma r-mediated phagocytosis and the IL-18/IFN-gamma -mediated molecular connection between innate and adaptive immunity in the lung. Blood 2002;100:4193-4200.
20. Shibata Y, Berclaz PY, Chroneos ZC, Yoshida M, Whitsett JA, Trapnell BC. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity 2001;15:557-567.
21. Bewig B, Wang XD, Kirsten D, Dalhoff K, Schafer H. GM-CSF and GM-CSF beta c receptor in adult patients with pulmonary alveolar proteinosis. Eur Respir J 2000;15:350-357.
22. Kitamura T, Tanaka N, Watanabe J, Uchida K, Kanegasaki S, Yamada Y, Nakata K. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med 1999;190:875-880.
23. Uchida K, Nakata K, Trapnell BC, Terakawa T, Hamano E, Mikami A, Matsushita I, Seymour JF, Oh-Eda M, Ishige I, et al. High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood 2004;103:1089-1098.
24. Bendtzen K, Svenson M, Hansen MB, Busch T, Bercker S, Kaisers U, Uchida K, Beck DC, Trapnell BC. GM-CSF autoantibodies in pulmonary alveolar proteinosis. N Engl J Med 2007;356:2001-2002. (Pubitemid 46740320)
25. Uchida K, Beck DC, Yamamoto T, Berclaz PY, Abe S, Staudt MK, Carey BC, Filippi MD, Wert SE, Denson LA, et al. GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. N Engl J Med 2007;356:567-579.
26. Svenson M, Hansen MB, Ross C, Diamant M, Rieneck K, Nielsen H, Bendtzen K. Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. Blood 1998;91:2054-2061.
27. Beck DC, Uchida K, Luisetti M, Keller G, Trapnell BC. Anti-GM-CSF antibodies isolated from pulmonary alveolar proteinosis (PAP) patients reproduce myeloid cell dysfunction in non-human primates. Am J Respir Crit Care Med 2007;175:A491.
28. Sakagami T, Beck D, Suzuki T, Uchida K, Wood RE, Carey BC, Wert SE, Ikegami M, Whitsett JA, Keller G, et al. Pulmonary alveolar proteinosis (PAP) reproduced in non-human primates. Am J Respir Crit Care Med 2009;179:A3030.
29. Sakagami T, Suzuki T, Uchida K, Carey BC, Wood RE, Wert S, Whitsett J, Luisetti M, Trapnell B. Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosis. N Engl J Med 2009;361:2679-2681.
30. Luisetti M, Rodi G, Perotti C, Campo I, Mariani F, Poszzi E, Trapnell BC. Plasmapheresis for treatment of pulmonary alveolar proteinosis. Eur Respir J 2009;33:1220-1222.
31. Nogee LM, Wert SE, Proffit SA, Hull WM, Whitsett JA. Allelic heterogeneity in hereditary surfactant protein B (SP-B) deficiency. Am J Respir Crit Care Med 2000;161:973-981.
32. Huffman JA, Hull WM, Dranoff G, Mulligan RC, Whitsett JA. Pulmonary epithelial cell expression of GM-CSF corrects the alveolar proteinosis in GM-CSF-deficient mice. J Clin Invest 1996;97:649-655. (Pubitemid 26057082)
33. Schoch OD, Schanz U, Koller M, Nakata K, Seymour JF, Russi EW, Boehler A. BAL findings in a patient with pulmonary alveolar proteinosis successfully treated with GM-CSF. Thorax 2002;57:277-280.
34. Mason RJ, Nellenbogen J, Clements JA. Isolation of disaturated phosphatidylcholine with osmium tetroxide. J Lipid Res 1976;17:281-284.
35. Ikegami M, Whitsett JA, Jobe A, Ross G, Fisher J, Korfhagen T. Surfactant metabolism in SP-D gene-targeted mice. Am J Physiol 2000;279:L468-L476.
36. Rennard SI, Basset G, Lecossier D, O'Donnell KM, Pinkston P, Martin PG, Crystal RG. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 1986;60:532-538.
37. Caparros D, Steenhouwer F, Marquette CH, Carpentier F, Foulet A. Rev Mal Respir 1994;11:63-66. (Pulmonary alveolar proteinosis. A sequential analysis of the alveolar cell population after complete pulmonary lavage. Apropos of a case).
38. Bonfield TL, Farver CF, Barna BP, Malur A, Abraham S, Raychaudhuri B, Kavuru MS, Thomassen MJ. Peroxisome proliferator-activated receptor-gamma is deficient in alveolar macrophages from patients with alveolar proteinosis. Am J Respir Cell Mol Biol 2003;29:677-682.
39. Martinez-Moczygemba M, Doan ML, Elidemir O, Fan LL, Cheung SW, Lei JT, Moore JP, Tavana G, Lewis LR, Zhu Y, et al. Pulmonary alveolar proteinosis caused by deletion of the GM-CSFralpha gene in the x chromosome pseudoautosomal region 1. J Exp Med 2008;205:2711-2716.
40. Scott CL, Hughes DA, Cary D, Nicola NA, Begley CG, Robb L. Functional analysis of mature hematopoietic cells from mice lacking the betac chain of the granulocyte-macrophage colony-stimulating factor receptor. Blood 1998;92:4119-4127.
41. Presneill JJ, Nakata K, Inoue Y, Seymour JF. Pulmonary alveolar proteinosis. Clin Chest Med 2004;25:593-613 (viii).
42. Bonfield TL, Russell D, Burgess S, Malur A, Kavuru MS, Thomassen MJ. Autoantibodies against granulocyte macrophage colony-stimulating factor are diagnostic for pulmonary alveolar proteinosis. Am J Respir Cell Mol Biol 2002;27:481-486.
43. Kavuru MS, Bonfield TL, Thomassen MJ. Plasmapheresis, GM-CSF, and alveolar proteinosis. Am J Respir Crit Care Med 2003;167:1036-1037.
44. Dalrymple H, Malur A, Gagnon G, Marshall I, Kavuru MS, Barna B, Thomassen MJ. Rituximab depletes B-lymphocytes and improves symptoms in pulmonary alveolar proteinosis. J Allergy Clin Immunol 2008;121:S225.
45. Kuroki Y, Tsutahara S, Shijubo N, Takahashi H, Shiratori M, Hattori A, Honda Y, Abe S, Akino T. Elevated levels of lung surfactant protein a in sera from patients with idiopathic pulmonary fibrosis and pulmonary alveolar proteinosis. Am Rev Respir Dis 1993;147:723-729.
46. Tanaka N, Watanabe J, Kitamura T, Yamada Y, Kanegasaki S, Nakata K. Lungs of patients with idiopathic pulmonary alveolar proteinosis express a factor which neutralizes granulocyte-macrophage colony stimulating factor. FEBS Lett 1999;442:246-250.
47. Paine R III, Morris SB, Jin H, Wilcoxen SE, Phare SM, Moore BB, Coffey MJ, Toews GB. Impaired functional activity of alveolar macrophages from GM-CSF- deficient mice. Am J Physiol 2001;281:L1210-L1218.
48. Bozinovski S, Jones J, Beavitt SJ, Cook AD, Hamilton JA, Anderson GP. Innate immune responses to LPS in mouse lung are suppressed and reversed by neutralization of GM-CSF via repression of TLR-4. Am J Physiol 2004;286:L877-L885.
49. Campbell IK, Bendele A, Smith DA, Hamilton JA. Granulocytemacrophage colony stimulating factor exacerbates collagen induced arthritis in mice. Ann Rheum Dis 1997;56:364-368.
50. McQualter JL, Darwiche R, Ewing C, Onuki M, Kay TW, Hamilton JA, Reid HH, Bernard CC. Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. J Exp Med 2001;194:873-882.
51. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Natl Rev 2008;8:533-544.
52. Seymour JF, Presneill JJ, Schoch OD, Downie GH, Moore PE, Doyle IR, Vincent JM, Nakata K, Kitamura T, Langton D, et al. Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis. Am J Respir Crit Care Med 2001;163:524-531.
53. Reed JA, Ikegami M, Cianciolo ER, Lu W, Cho PS, Hull W, Jobe AH, Whitsett JA. Aerosolized GM-CSF ameliorates pulmonary alveolar proteinosis in GM-CSF- deficient mice. Am J Physiol 1999;276:L556-L563.
54. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-2581. (Pubitemid 38758544)
55. Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M, Webster AD. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003;48:2146-2154.
56. King C, Ilic A, Koelsch K, Sarvetnick N. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 2004;117:265-277. (Pubitemid 38496245)
57. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345:747-755.
58. Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, Peng A, Villicana R, Jordan SC. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008;359:242-251.